Pseudomonas cepacia colonization of or infection in patients with cystic fibrosis (CF) has been associated with increased morbidity and premature death. However, current data on national incidence may be biased because of interlaboratory differences in the methods of culturing sputa of patients with CF. We conducted three tests to evaluate the proficiency of microbiology laboratories at CF centers in identifying and isolating P. cepacia and to assess the value of using selective media for P. cepacia (P. cepacia agar and oxidation-fermentation polymyxin-bacitracin-lactose medium [OFPBL]) to recover P. cepacia from specimens simulating sputa of patients with CF. In test 1, we evaluated the proficiency of laboratories in identifying P. cepacia. Of 111 laboratories tested, 105 (95%) correctly identified P. cepacia. In test 2, we evaluated the proficiency of laboratories in isolating P. cepacia from simulated CF sputum specimens. Only 36 (32%) of 115 laboratories detected P. cepacia. Recovery of the microorganism was associated with the use of P cepacia agar or OFPBL; 14 (95%) of 15 laboratories using P. cepacia agar or OFPBL (or both) versus 22 (22%) of 100 laboratories not using either medium recovered P. cepacia (P < 0.0001, Fisher exact test, one tailed). Laboratories failing test 2 were requested to use a selective medium for P. cepacia in a repeat test; 73 (97%) of 75 laboratories using P. cepacia agar or OFPBL (or both) versus 0 of 4 laboratories not using either medium detected P. cepacia (P < 0.0001, Fisher exact test, one tailed). Our studies show that (i) microbiology laboratories at CF centers are proficient in identifying P. cepacia, and (ûi) the use of selective media for P. cepacia enhances recovery of the microorganism in simulated sputum specimens. Therefore, we recommend the use of selective media for P. cepacia in laboratories processing sputa of patients with CF.
Pseudoinonas cepacia colonization of patients with cystic fibrosis (CF) has been associated with adverse clinical outcome (4) (5) (6) . In our previous study comparing patients with similar severity of underlying pulmonary CF, those colonized with P. cepacia were hospitalized more frequently for pulmonary exacerbations after their colonization and died earlier than controls (5) . Although recent increases in yearly incidence of P. cepacia colonization have been reported by some large CF centers (4) (5) (6) , the national incidence has not been well determined. Microbiology laboratories at CF centers differ in their methods of isolating and identifying P. cepacia. P. cepacia may be easy to identify once isolated in pure culture, but its presence in the sputum of a patient with CF may be difficult to detect. Other microorganisms prevalent in the CF patient's respiratory tract, including PseudonIonas aeruginosa and Staphylococcus aureus, easily overgrow P. Cepacia on most isolation media. Recently, two selective media for P. cepacia, P. cepacia agar and oxidation-fermentation polymyxin-bacitracin-lactose medium (OFPBL) were formulated to enhance the recovery of P. cepacia in the sputa of CF patients. In this study, we evaluated the proficiency of microbiology laboratories at CF centers in the United States in isolating and identifying P. cepacia, and we assessed the role of P. cepacia agar and OFPBL in the laboratory recovery of P. cepacia from specimens simulating sputa of patients with CF. (Table 1) . Three (3%) laboratories were unable to recover microorganisms from the test specimens, and three laboratories identified P. cepacia only to the genus level (two used the API 20E system [Analytab Products], and one used limited conventional tests).
MATERIALS AND METHODS

In
All 15 laboratories using P. cepacia agar or OFPBL (or both) isolated and identified the microorganism. However, the rates of detection of P. cepacia by laboratories using selective media (15 of 15, 100%) and those not using the selective media (90 of 96, 94%), were not significantly different (NS; FET) because test 1 specimens contained none or only a few colonies of P. aeruginosa and S. aureus.
Isolation of P. cepacia. In test 2, only 36 (32%) of 115 participating laboratories detected P. cepacia in the test specimens. This was significantly lower than the 95% rate of isolation of the microorganism in test 1 (P < 0.0001, FET, one tailed).
We examined factors potentially affecting the results of tests 1 and 2. The only identifiable difference between the two tests was the increase in the concentrations of P. aeruginosa and S. aureus in test 2 specimens, which made visualization of P. cepacia on routine primary isolation media difficult. We found no differences in (i) the mean time of transporting specimens from the CDC to laboratories at CF centers (66.8 ± 4.3 h in test 1 versus 67.1 ± 3.7 h in test 2; P = NS, Student t test) or (ii) the mean time of holding specimens after their arrival at the laboratories (13.3 3.1 h in test 1 versus 7.1 ± 1.7 h in test 2, P = NS, Student t test). In addition, for both tests each laboratory used the same inoculation techniques, media, and biochemical tests to identify P. cepacia.
To determine the value of using selective media for P. cepacia, we compared the methods of processing sputum in laboratories isolating P. cepacia with those in laboratories unable to isolate P. cepacia in test 2. The two groups were comparable except in their use of some primary isolation media (Table 2 ). Laboratories detecting P. cepacia were more likely than others to have used P. c-epacia agar, OFPBL, and eosin methylene blue. However, the use of a medium by a laboratory did not always result in the recovery of P. cepacia on that medium. Although the use of eosin methylene blue was correlated with isolation of P. cepacia, only 5 (17%) of 28 laboratories using eosin methylene blue detected P. cepacia on this medium. On the other hand, of 15 laboratories using P. cepacia agar or OFPBL or both (5 used OFPBL, 9 used P. cepacia agar, and 1 used both media), 14 (95%) isolated P. cepacia on these media. The combined rate of P. cepacia isolation on the two media selective for P. cepacia (14 of 15, 95%) was significantly greater than the rate of P. cepacia isolation on all other media (22 of 100, 22%; P < 0.0001, FET, one tailed).
The results of test 3 confirmed our findings in test 2. Of 75 laboratories using P. cepacia agar or OFPBL or both, 73 (97%) detected P. cepacia; in contrast, of 4 laboratories not using selective media for P. cepacia, none detected the microorganism (P < 0.0001, FET, one tailed). In addition, of the 73 successful laboratories, 47 (65%) recovered P. cepacia only on P. cepacia agar or OFPBL. The isolation rate of P. cepacia on each of the other media was .23% (Table 3 ).
DISCUSSION
Our study shows that most CF center microbiology laboratories are proficient in identifying P. cepacia. Laboratories were able to recover and subsequently identify P. cepacia when isolated colonies of the microorganism were distinctly (1) . In this study, laboratories using either or both media consistently recovered P. cepacia in test specimens containing high concentrations of mucoid P. aeruginosa and S. aureus.
Although our study was conducted with artificial sputum seeded with microorganisms, our test material closely simulated clinical specimens from CF patients (2-3). Therefore, laboratory use of a P. cepacia selective medium for processing CF sputum specimens may be expected to enhance isolation of P. cepacia by inhibiting the growth of other prevalent microorganisms and allowing visualization of P. cepacia colonies.
Because P. cepacia selective media had not been previously available for general use in CF centers, it is likely that some P. cepacia in the sputum of CF patients had not been identified in the past. Therefore, reported incidences of P. cepacia colonization and infection from such centers should be considered as minimum estimates. Moreover, possible ascertainment bias should be entertained when increases in current incidence are perceived at centers now using selective media for P. cepacia.
Recently, the CDC Hospital Infections Program and the CF Foundation developed and circulated to CF centers in the United States a protocol recommending the routine use of P. cepacia selective media in microbiology laboratories. Most CF centers have adopted the standardized technique and are collaborating with CDC and the CF Foundation in a national study to prospectively determine the incidence of P. cepacia colonization of and infection in CF patients. We hope that this and other studies will contribute to a better understanding of the epidemiology and pathophysiology of colonization and infection by P. cepacia of patients with CF.
